Last reviewed · How we verify
AdVEGFXC1
At a glance
| Generic name | AdVEGFXC1 |
|---|---|
| Also known as | XC001 |
| Sponsor | XyloCor Therapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AdVEGFXC1 CI brief — competitive landscape report
- AdVEGFXC1 updates RSS · CI watch RSS
- XyloCor Therapeutics, Inc. portfolio CI